Biohealth Innovation - 305th Edition

BioHealth Innovation

If you are having trouble viewing this email, please click here

May 30, 2018

BioHealth Innovation Appoints Jarrod Borkat as new Vice Chairman of the Board

MedImmune Sr. Director, Partnering & Strategy filling role previously held by Emergent BioSolutions CEO, Daniel J. Abdun-Nabi

BioHealth Innovation, Inc. (BHI) announced that its Board of Directors has unanimously approved the appointment of MedImmune Sr. Director, Partnering & Strategy, Jarrod Borkat as new Vice Chairman. MedImmune, the global biologics research and development arm of AstraZeneca, is a Founding Partner of BHI and continues to be a leader in building the BioHealth Capital Region. BHI would like to thank Emergent BioSolutions CEO, Daniel J. Abdun-Nabi, for his service as Vice Chairman. He will remain as a member of the Board of Directors. Mr. Abdun-Nabi also previously served as chairman of the Maryland Life Sciences Advisory Board (LSAB) and currently serves on Maryland Governor Larry Hogan’s Excel Board.

Margaret Anderson, Managing Director at Deloitte Consulting LLP, sits down with host Rich Bendis for this episode of BioTalk. They discuss her career path, putting patients at the center of biomedical and public health, and engaging with all sectors. Margaret Anderson is a Managing Director at Deloitte Consulting LLP focused on using strategy to make organizations, agencies, and programs stronger and more laser focused on outcomes for patients. Her career has traversed biomedical and public health policy and she’s motivated by the change she’s seen in bringing treatments and solutions for patients forward.

As used in this podcast, “Deloitte” means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Listen now on iTunes , Google Play , and TuneIn.

Kite Pharma Announces New Worldwide Facilities Including Expanded Collaboration with National Cancer Institute to Support Cell Therapy Pipeline in new 26K sf facility in Gaithersburg, MD

Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.

175,000 sq. ft. Development in Bethesda Will Focus on Creating “Bethesda Bio” — MCEDC

StonebridgeCarras and The Donohoe Companies announced plans today for their project at 8280 Wisconsin Avenue which will focus its 175,000 square feet of commercial space on bringing life sciences to the Bethesda Central Business District (CBD). StonebridgeCarras and Donohoe’s vision for the project is to capitalize on two converging trends: employers locating their offices in live, work and play environments with access to mass transportation; and life sciences companies co-locating near thought leaders and institutions driving research and advancement.

Marketing Communications Internship Opening at BHI

BioHealth Innovation, Inc. (BHI) is a nonprofit organization focused on supporting BioHealth entrepreneurs and related industry growth in Montgomery County and the BioHealth Capital Region (Maryland, D.C. and Virginia). BHI is seeking an energetic and motivated Marketing Intern to assist with communications and marketing-related projects. This position is estimated to be 15-25 hours per week, would start immediately, and continue for 12 weeks. In addition to the responsibilities listed below, the intern may attend meetings and programs to understand the full work of BHI and how the organization accomplishes its mission through constituent outreach and support, commercialization and partnership activity.

Iowa AgriTech Accelerator announces startups for program’s 2018 cohort - VakSea accepted to participate

The Iowa AgriTech Accelerator is a mentor-led accelerator focused on AgTech innovations. The Accelerator is led by innovators and leaders in several areas of agriculture, and seeks startups ready to change the status quo.

MockV Solutions Announces Collaboration with NIH for Predicting Viral Clearance During Small Scale Bioprocess Development – MockV Solutions

MockV Solutions, Inc. (MockV or the Company), a company developing innovative products to analyze virus clearance during process development, announced today that it will be collaborating with the Vaccine Production Program of the Vaccine Research Center/National Institute of Allergy and Infectious Diseases/National Institutes of Health (VRC, NIAID, NIH) to evaluate its lead product candidate, the MVM-MVP Kit. The MVM-MVP Kit contains a non-infectious “Mock Virus Particle” (MVP) spiking surrogate that mimics the physicochemical characteristics of Minute Virus of Mice (MVM), a small and physiochemically resistant parvovirus, used as a universal standard for assessing viral clearance during process validation studies. The intention of this collaboration is to determine if the non-infectious MVP could be used as an accurate and economic indicator of MVM clearance during small scale bioprocess development studies.

Maryland Tech Council Announces Winners of 30th Annual Industry Awards | Business Wire

The Maryland Tech Council (MTC), Maryland’s largest technology trade association, announced the winners of its 30th Annual Industry Awards during a celebration and ceremony at The Hotel at the University of Maryland attended by more than 550 business leaders from around the state.

Johns Hopkins startup gets funding from company turning research into businesses - Technical.ly Baltimore

A company that works to turn intellectual property into businesses is backing a new Johns Hopkins startup developing therapeutics to treat cancer.

Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage (NYSE:RNN)

Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, advances its ongoing Phase 2a study of RX-3117 in combination with Abraxane® in first-line patients with metastatic pancreatic cancer following a recently completed routine Safety Monitoring Committee (SMC) review.

MdBio Foundation Names Laurel 12th Grader Katy Wnuk-Fink as Maryland BioGENEius Finalist - Business Wire

The MdBio Foundation, a non-profit that provides STEM education and workforce development to underserved communities, today announced that Katy Wnuk-Fink – a senior from Laurel who attends Reservoir High School – was named winner of the 2018 Maryland BioGENEius Challenge, the premier competition for high school students that recognizes outstanding original research in biotechnology for healthcare, sustainability, and the environment. As the Maryland BioGENEius finalist, Wnuk-Fink will represent the state in the International BioGENEius Challenge at the BIO International Convention in Boston in June.

TEDCO awards $7.1 million to 25 stem cell projects in Maryland - Baltimore Business Journal

Maryland Technology Development Corp. has doled out $7.1 million to 25 companies and researchers working on stem cell products and medical therapies.

Protenus Recognized as One of the Best Places to Work in Healthcare in 2018 - Protenus

Protenus has been selected by Modern Healthcare as one of the 2018 Best Places to Work in Healthcare. The complete list of this year’s winners, in alphabetical order, is available here. Modern Healthcare will publish a special supplement featuring ranked lists of all the winners along with the October 1 issue.

Paragon Bioservices Recognized as Life Science Company of the Year by Maryland Tech Council - Paragon Bioservices, Inc.

Paragon Bioservices, Inc. (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, was named the 2018 Life Science Company of the Year by the Maryland Tech Council (MTC). The announcement came at MTC’s 30th Annual Industry Awards held last night in the Hotel at the University of Maryland in College Park.

Grand Prize Winner for the Innovation for Impact Prize Announced by SoBran and the Maryland Tech Council

SoBran BioScience, a division of SoBran Inc, and a leading provider of pre-clinical GLP contract research announced the grand prize winner of the Innovation for Impact Prize sponsored in partnership with the Maryland Tech Council (MTC). This Grand Prize was awarded last night at the MTC 30th Anniversary Industry Awards Celebration.

KEI Sues NIH Over Gilead CAR-T Patents - PharmaLive

A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.

KEI calls itself a “not for profit non government organization that searches for better outcomes, including new solutions, to the management of knowledge resources. KEI is focused on social justice, particularly for the most vulnerable populations, including low-income persons and marginalized groups.”

SBA Seeks Grant Applications from Organizations - Hudson Valley News Network

The U.S. Small Business Administration, under its Federal and State Technology (FAST) Partnership Program, is soliciting grant applications from New York organizations to help boost the development of technology from small businesses.

Nostopharma LLC is working on a cure for a common surgery complication - Washington Business Journal

A complication from surgery can cost tens of thousands of dollars and require more surgery to correct — but a young Maryland startup is cooking up a more affordable and less invasive solution.

NIST Revises Intellectual Property Rights - Federal Labs

Join the FLC on Tuesday, May 22 at 1:00 p.m. EDT for an inside look into these new regulations with NIST’s Courtney Silverthorn. To register for this webinar, visit http://connect.federallabs.org/new-t2-regulations-what-you-need-to-know.

RFA-HL-19-018: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.

RFA-HL-19-017: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Funding Opportunity Announcement (FOA) invites SBIR grant applications from SBCs to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners.

Top 5 Trends in the Pharmaceutical Industry in 2018

This white paper takes an in depth look at trends in the pharmaceutical industry that are anticipated to make a significant impact on the sector in 2018. Industry professionals can leverage this information to make the course adjustments that will give their companies a competitive edge in the market.

Medical Fish Skin Company Kerecis Receives the Industry Award for Entrepreneurship from the President of Iceland

Today the President of Iceland awarded Kerecis the Industry Award for Entrepreneurship. Kerecis is the creator, manufacturer and patent holder of revolutionary, fish-skin-based therapeutic products that speed up the healing process of human wounds and repair tissue damage.

Pace of exits picks up for venture development organizations in Q1 - SSTI

Venture development organizations (VDO), nonprofit organizations across the country investing in innovation startups to help grow their regional economies as well as earn a respectable return, saw at least 20 exits in the first quarter of 2018, based on data entered on Pitchbook.com. Here are some examples from the quarter:

Mount Sinai's Icahn medical school launches $10 million investment fund | Crain's New York Business

The Icahn School of Medicine at Mount Sinai has created a $10 million accelerator fund to speed up the commercialization of research at the school. It's starting with two investments in drug-development ventures.

Raising your next round? Six qualities that define top healthcare VCs - MedCity News

Founders can become myopic during the long, stressful process of fundraising. Many focus solely on the amount of money they’re going to raise, their valuation, and the brand name of the investors they are pitching.

A look inside Tufts, Biolabs new biotech incubator Launchpad in downtown Boston - Boston Business Journal

Tufts University has joined the biotech incubator craze, launching a coworking space in Boston earlier this year that organizers hope will foster another life sciences cluster in the heart of the city.

Boston Children’s, Red Hat develop cloud platform for images | Health Data Management

Boston Children’s Hospital has teamed up with open-source solution provider Red Hat to create a web-based medical image platform that will speed the time it takes to share and analyze life-saving images.

AZBio initiative aims to cure funding gap that ails Arizona

Trying to build on Arizona’s significant investments in the life science discovery and healthcare delivery infrastructure, the state’s leaders are focused on bridging the funding gap that slows the growth of Arizona-based life science companies. Leaders of Arizona’s life science sector share a drive to accomplish a common goal: accelerate the growth of local companies that are developing and delivering innovative treatments that truly change lives.

IPO Slowdown Leads Silicon Valley Venture Giant NEA to Sell $1 Billion Worth of Startup Stakes - WSJ

New Enterprise Associates, one of Silicon Valley’s largest venture-capital firms, plans to sell off a big chunk of its startup investments in response to a dearth of initial public offerings, according to people familiar with the discussions.